Patient Experience With Once-daily Deutetrabenazine Extended-release Tablets for the Treatment of Tardive Dyskinesia in Individuals With Prior Valbenazine Use
Rakesh Jain1, Martijn Konings2, Maurice Driessen3, Sameer Kotak4, Pooja Gandhi2
1Texas Tech University School of Medicine-Permian Basin, 2Teva Branded Pharmaceutical Products R&D LLC, 3Teva Pharmaceuticals Europe B.V, 4Yorker Health Corp.
Objective:
To explore patient-reported experiences with once-daily (QD) deutetrabenazine extended-release tablets among those with prior valbenazine use (PVU).
Background:
Deutetrabenazine is used for treatment of tardive dyskinesia (TD) and Huntington disease (HD)–related chorea and can be administered QD or twice daily (BID). A survey study explored patient-reported experience with QD deutetrabenazine extended-release tablets. This subgroup analysis explored responses from participants taking deutetrabenazine QD for their TD who reported PVU.
Design/Methods:
This noninterventional, prospective, cross-sectional, IRB-approved survey included adults with TD/HD-related chorea taking deutetrabenazine QD. Participants in the Teva Shared Solutions patient support program who completed/were due for their 12-week nurse outreach phone call were eligible. Only TD results are reported in this analysis.
Results:
209 participants with TD completed the survey, with 54 participants reporting PVU (mean age 56.7 years, 78% female, 91% White) and 100 participants reporting no prior TD medication (de novo; 61.7 years, 70% female, 97% White). ≥82% of participants in both groups liked that their doctor could adjust their dose. >94% of participants in both groups reported that their extra movements were very much/much/minimally improved with deutetrabenazine QD. In both groups, >77% strongly agreed/agreed that since starting deutetrabenazine QD, reduction in their extra movements had improved their comfort in social settings and emotional well-being. Most participants reported it was very/somewhat easy to take deutetrabenazine QD (PVU: 96%; de novo: 99%) and 96% across groups strongly agreed/agreed that they will continue taking deutetrabenazine QD. 91% (PVU) and 89% (de novo) reported satisfaction with deutetrabenazine QD.
Conclusions:
Most participants with TD who reported previously using valbenazine and those who initiated deutetrabenazine QD de novo reported improvements in their extra movements and overall satisfaction with deutetrabenazine QD.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.